Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

She had been treated for acute myeloid leukemia once before, but the fast-growing blood cancer came back. A bone marrow ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...